相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients EDITORIAL COMMENT
Rishi R. Sekar et al.
UROLOGY (2023)
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Jeroen van Dorp et al.
NATURE MEDICINE (2023)
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
Pradeep S. Chauhan et al.
npj Precision Oncology (2023)
HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.
Jason Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).
Matt D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Utility of ctDNA in predicting outcome and pathological complete response in patients with bladder cancer as a guide for selective bladder preservation strategies.
Lars Dyrskjøt et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
Daniel M. Geynisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
Brendan John Guercio et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.
Shilpa Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
Daniel P. Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
NEXT: A single-arm, phase 2, open-label study of adjuvant nivolumab after completion of chemoradiation therapy in patients with localized muscle-invasive bladder cancer.
Sumati Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
Petros Grivas et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives
Sen Liu et al.
JOURNAL OF ADVANCED RESEARCH (2022)
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados et al.
EUROPEAN UROLOGY (2022)
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
Christian Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.
Richard Cathomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
ANTICIPATE: A phase I/II, open-label, multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy (NAC) in patients with muscle invasive bladder cancer (MIBC).
Matt D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.
Nieves Martinez Chanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.
Elizabeth R. Plimack et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4).
Sergio Vazquez-Estevez et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Comparative analysis of urinary and tissue tumor DNA in muscle-invasive bladder cancer by boosted whole-exome sequencing
J. Zang et al.
ANNALS OF ONCOLOGY (2022)
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Giuseppe Basile et al.
CLINICAL CANCER RESEARCH (2022)
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Christopher J. Hoimes et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Russell E. N. Becker et al.
EUROPEAN UROLOGY (2021)
First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
Dean F. Bajorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
Arjun Vasant Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023.
Monika Joshi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.
Parminder Singh et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.
Richard Cathomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial
Matthew Zibelman et al.
JOURNAL OF UROLOGY (2021)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2021)
Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
N. Martinez Chanza et al.
ANNALS OF ONCOLOGY (2021)
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Arjun Vasant Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
Petros Grivas et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
Xavier Garcia del Muro et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
Matt D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles et al.
NATURE (2021)
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
D. F. Bajorin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Aurelie Kamoun et al.
EUROPEAN UROLOGY (2020)
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
Andrea Necchi et al.
EUROPEAN UROLOGY (2020)
Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.
Shilpa Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).
Andrew James Weickhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.
Juan Francisco Rodriguez-Moreno et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
Enrique Grande et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.
Christopher J. Hoimes et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.
Hristos Z. Kaimakliotis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
Andrea Necchi et al.
EUROPEAN UROLOGY (2020)
Treatment of muscle-invasive and advanced bladder cancer in 2020
Vaibhav G. Patel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]
U. N. Vaishampayan et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
A. Alva et al.
ANNALS OF ONCOLOGY (2020)
Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer
Xu Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk et al.
NATURE MEDICINE (2020)
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Jianjun Gao et al.
NATURE MEDICINE (2020)
Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
T. B. Powles et al.
ANNALS OF ONCOLOGY (2020)
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Benjamin Miron et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Emil Christensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).
Jianjun Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular and histopathology directed therapy for advanced bladder cancer
Constantine Alifrangis et al.
NATURE REVIEWS UROLOGY (2019)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles et al.
NATURE MEDICINE (2019)
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)
Valeria Panebianco et al.
EUROPEAN UROLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
Andrea Necchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience
Nicholas J. Giacalone et al.
EUROPEAN UROLOGY (2017)
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
Roland Seiler et al.
EUROPEAN UROLOGY (2017)
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer
Catherine Thompson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Sam S. Chang et al.
JOURNAL OF UROLOGY (2017)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
Peter A. Humphrey et al.
EUROPEAN UROLOGY (2016)
Trends in Stage-Specific Incidence Rates for Urothelial Carcinoma of the Bladder in the United States: 1988 to 2006
Matthew E. Nielsen et al.
CANCER (2014)
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
Gareth Griffiths
JOURNAL OF CLINICAL ONCOLOGY (2011)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I. Liakou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
HB Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924
CN Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
